Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo- and active-controlled study of MK-6913 for vasomotor symptoms (hot flashes)
2009-016070-33Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-6913 in vasomotor symptoms (3 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in weekly hot flash frequency at 4 weeks and Change from baseline in weekly hot flash severity score at 4 weeks. Started Nov 2009; status: terminated.
02
Drugs
MK-6913
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on 2009-016070-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016070-33.